Navigation Links
Researchers present new findings on cancer and gene therapy
Date:4/7/2011

WASHINGTON, April 7, 2011 DNA's role as the master blueprint of the cell means that even small sequence changes can have catastrophic consequences. For this reason, much of our understanding of cancer development comes from studying how cells copy DNA and repair sequence errors -- and how these processes can go wrong.

Next week, a thematic program at the American Society for Biochemistry and Molecular Biology's annual meeting at the Experimental Biology 2011 conference in Washington, D.C., will bring together researchers from across the country to discuss recent developments in DNA replication, recombination, and repair, and the importance of these activities in cancer and gene therapy. It will launch Sunday in Room 206 of the Walter E. Washington Convention Center.

Theme organizers Marlene Belfort from the Wadsworth Center at the New York State Department of Health and Joann B. Sweasy from Yale University have assembled a roster of experts who will present recent discoveries in how cells manage the process of copying DNA, adding and removing stretches of sequence in the genome, and the consequences of when mistakes occur.

Aberrant DNA Repair, Genomic Instability and Cancer: The first platform session will be held from 9:55 a.m. to 12:10 p.m. Sunday. Cells accumulate at least 20,000 DNA lesions a day that require repair to maintain healthy cellular function. Because maintaining a stable genome is crucial to preventing disease, research on aberrant DNA repair and other processes that alter DNA sequence are important aspects of understanding the development of cancer. This session will feature researchers from the University of Texas M.D. Anderson Cancer Center, Yale University and the Massachusetts Institute of Technology.

Site-Specific Recombination in Chromosome Dynamics and Gene Therapy: The second round of talks, to be held from 3:45 p.m. to 6 p.m. Monday, will focus on gene therapy, a promising area of research that is developing techniques to correct mutations as a means of preventing or treating disease. The three talks will feature researchers from the University of Texas at Austin, the University of Washington and the University of Pennsylvania describing specific applications currently under study for targeted gene correction and genome engineering.

Replication of Noncanonical DNA Sequences and Genomic Instability: The third platform session in the program, 9:55 a.m. to 12:15 p.m. Tuesday, will highlight research on noncanonical, or nonstandard, DNA structures that can destabilize DNA strands and lead to breakage and mutations. This session will present research on the mutation-causing effects of non-canonical DNA structures and the mechanisms cells use to copy DNA and repair damage to avoid mutations and cancer. Scientists from the Robert Wood Johnson School of Medicine, Yale University and the University of Texas M.D. Anderson Cancer Center will speak.

Retroelements in Genome Plasticity and Cancer: In the final round of talks, to be held from 1:45 p.m. to 4 p.m. Wednesday, three researchers will talk about retroelements, stretches of genetic sequence that can copy themselves and insert the copy in different places in the genome. The insertion of retroelements can lead to diverse outcomes, some beneficial and some lethal, and this session will cover both aspects. A researcher from the Cleveland Clinic will describe his studies on a retrovirus that may cause prostate cancer, and two scientists from the Wadsworth Center will talk about retrotransposons and their contrasting functions in genetic diversity and aging.


'/>"/>

Contact: Angela Hopp
ahopp@asbmb.org
301-634-7389
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related medicine news :

1. Fox Chase researchers find that fish oil boosts responses to breast cancer drug tamoxifen
2. Fox Chase researchers report that naproxen reduces tumors in a mouse model of colon cancer
3. UPCI, Pitt researchers present findings of cancer studies at AACR 102nd Annual Meeting
4. Using MRI, researchers may predict which adults will develop Alzheimers
5. Researchers use zebrafish to identify new gene linked to melanoma
6. Researchers identify the metabolic signaling pathway responsible for dyslipidemia
7. Fox Chase researchers develop a screen for identifying new anticancer drug targets
8. Dangerous blood pressure increases during exercise can be blocked, UT Southwestern researchers find
9. Researchers mimic bodys own healing potential to create personalised therapies for inflammation
10. BATTLE researchers identify new biomarkers for EGFR inhibition
11. Researchers need to engage lesbian, gay, bisexual, and transginder populations in health studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water is ... leading bottled water brand owners that topped the list as a result of their ... conversion. The premier brand was Tibet 5100, a top notch water company that specializes ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... Diego, will bring together more than 200 of the country’s top healthcare executives ... future. , “The true benefit of the Forum is the provider-centric perspective, experience, ...
(Date:2/10/2016)... ... , ... Armune BioScience signed a definitive agreement with ARCpoint ... across the country. Launched in April of 2015, Apifiny is the only cancer specific, ... order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized ...
(Date:2/10/2016)... ... February 10, 2016 , ... A national ... Congress and Expo event March 9-11, 2016. Hosted by Ohio's Bureau of Worker's ... , As the longest running and largest worker's compensation event in Ohio, organizers ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... February 26th: Amateur & Professional Divisions - Time: 7:00pm – 10:00pm | ... | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: http://www.facebook.com/uspolesportsfederation ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... and SAN DIEGO , ... Inc., a global leader in viral gene therapy manufacturing, ... treatments for congestive heart failure and other chronic diseases, ... a scalable manufacturing process and produce cGMP-grade RT-100 (Ad5.hAC6) ... --> --> ...
(Date:2/10/2016)... 2016 Immune Pharmaceuticals Inc. (NASDAQ: IMNP ... it has filed a patent application directed to the ... --> --> The new ... Ceplene (histamine dihydrochloride) in combination with immune checkpoint inhibitors. ... efficacy of Ceplene and IL-2 therapy in patients with ...
(Date:2/10/2016)... Feb. 10, 2016  Oxis International Inc. (OTC/QB: OXIS) ... was described as a "clinical trial triumph" after one ... into complete cancer remission. Daniel Vallera ... Masonic Cancer Center. --> Daniel Vallera ... Masonic Cancer Center. --> An article ...
Breaking Medicine Technology: